好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebellar Inhibition Using Low-Intensity Focused Ultrasound
Neuro-rehabilitation
S42 - Neuro-rehabilitation (3:54 PM-4:06 PM)
003

This study explores the feasibility of modulating cerebellar activity using low-intensity focused ultrasound (LIFUS) in humans.

The cerebellum has extensive connections to cortical structures such as the primary motor cortex (M1). Although established non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), can target the cerebellum, they lack the spatial focality to allow detailed investigations of the cerebello-cortical networks. Low intensity focused ultrasound (LIFUS) is a novel stimulation technique that uses acoustic waves above 20 KHz to alter neuronal excitability. LIFUS is capable of reaching deeper brain structures with greater focal width (2-4 mm) compared to TMS and tDCS. This makes LIFUS particularly well-suited to target portions of the cerebellum.

Using a paired LIFUS-TMS paradigm, we compared the effects of different cerebellar LIFUS (cbLIFUS) sonication durations on M1 excitability in healthy human subjects. The cerebellum was sonicated for a duration of 500 ms. Motor-evoked potential (MEP) amplitudes were measured pre-sonication (150 ms before), during sonications (150ms, 300ms, and 450 ms after the start of sonication) and post-sonication (150 ms after the completion of sonication). We also compared the effects of cbLIFUS to cerebellar TMS. 

Preliminary results in four subjects show that 300 ms and 450 ms of cbLIFUS resulted in inhibition of contralateral M1 excitability. However, the largest inhibition was observed at 150 ms post-sonication. When compared to cerebellar TMS, larger inhibition was observed with cbLIFUS at 300ms, 450 ms and post-sonication. The study is ongoing and more subjects are being recruited.

cbLIFUS is a safe option for cerebellar modulation in humans. In particular, cbLIFUS achieved greater M1 inhibition than cbTMS. These effects increased with sonication duration and appear to continue shortly after sonication ended.

Authors/Disclosures
Jean-Francois Nankoo, PhD (University Health Network)
PRESENTER
Dr. Nankoo has nothing to disclose.
No disclosure on file
Julianne Baarbé No disclosure on file
No disclosure on file
Andres M. Lozano, MD (Toronto Western Hosp) Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insightec. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Functional Neuromodulation.
Robert E. Chen, MD, MBBChir (Toronto Western Hospital) Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Paladin Labs. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Chen has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Canadian Journal of Neurological Sciences. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders. The institution of Dr. Chen has received research support from Canadian Institutes of Health Research. The institution of Dr. Chen has received research support from NIH. The institution of Dr. Chen has received research support from Natural Science and Engineering Research Council of Canada. Dr. Chen has received research support from Parkinson Foundation. The institution of Dr. Chen has received research support from National Organization for Rare Disease. The institution of Dr. Chen has received research support from Merz.